Opinion|Videos|November 4, 2024
CARTITUDE-4: Cilta-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
Panelists discuss how the CARTITUDE-4 trial results show cilta-cel's superior efficacy over standard of care therapies in treating relapsed/refractory multiple myeloma, potentially reshaping treatment paradigms for this patient population.
Advertisement
Episodes in this series
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
3
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
4
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
5